FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308399633> ?p ?o ?g. }

• W4308399633 abstract "<h3>Background</h3> Anticancer agents that render cancer cells susceptible to apoptosis and increase antitumor immunity may enhance clinical responses to immune checkpoint inhibitors. In this phase 1b/2 trial, we investigated the antitumor activity and safety of xevinapant, a first-in-class, potent, oral, small-molecule inhibitor of apoptosis proteins inhibitor which restores cancer cell sensitivity to apoptosis, in combination with the anti-PD-1 antibody nivolumab. <h3>Methods</h3> Eligible patients had histologically confirmed advanced or metastatic solid tumors that progressed on prior anti–PD-1/PD-L1 treatment, including small cell lung cancer (cohort 1), squamous cell carcinoma of the head and neck (cohort 2), gastrointestinal cancers with known microsatellite-high (MSI-H)/mismatch repair deficiency (MMRd) or other DNA-damage response (DDR) abnormalities (cohort 3), or platinum-resistant epithelial ovarian, endometrial, primary peritoneal or cervical cancer (with known MSI-H/MMRd, <i>BRCA1/2</i> mutations, or other DDR abnormalities; cohort 4). In the dose-escalation part of the trial (part A), patients received xevinapant 150 or 200 mg/day on days 1-10 and days 15-24 plus nivolumab 240 mg on days 1 and 15 of a 28-day cycle. The primary objective of part A was to determine the recommended phase 2 dose (RP2D). In the phase 2 basket trial (part B), patients received xevinapant plus nivolumab at the RP2D; the primary endpoint was objective response rate (ORR). <h3>Results</h3> Eleven patients were enrolled in part A; 3 patients received xevinapant 150 mg/day and 8 received 200 mg/day. No dose-limiting toxicities during the observation period (28 days) or grade ≥3 treatment-related adverse events (TRAEs) were reported. The RP2D was established as xevinapant 200 mg/day (days 1-10 and 15-24) plus nivolumab 240 mg (days 1 and 15) per 28-day cycle.¹ In part B, 35 patients (n=8 cohorts 1-3, n=11 cohort 4) received xevinapant plus nivolumab at the RP2D. Most patients (60.0%) had stage IV disease and all patients had received prior chemotherapy treatment. At data cutoff (April 6, 2022), the ORR was 2.9%, with 1 partial response (cohort 4; endometrial cancer); 15 patients (42.9%) had stable disease. Thirty-four patients (97.1%) had discontinued treatment; the most common reason was disease progression (26 patients; 74.3%). Median PFS across cohorts was 1.9 months (95% CI, 1.7-2.7); median OS was 11.7 months (95% CI, 6.0-15.9). TRAEs occurred in 30 patients (85.7%); grade ≥3 TRAEs in 9 patients (25.7%). No treatment-related deaths were reported. <h3>Conclusions</h3> Xevinapant plus nivolumab had a tolerable safety profile in patients with heavily pretreated solid tumors but limited clinical activity in this immunotherapy-refractory population. <h3>Acknowledgements</h3> This trial was sponsored by Debiopharm. Medical writing support was provided by Sophie Saunders of ClinicalThinking and was funded by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945). <h3>Trial Registration</h3> NCT04122625 (ClinicalTrials.gov) <h3>Reference</h3> Azaro Pedrazzoli AB, Moreno V, Gomez-Roca CA, <i>et al</i>. Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment. <i>Ann Oncol</i> 2020;<b>31</b>(Suppl 4):Abstract 560P. <h3>Ethics Approval</h3> The trial protocol was approved by the independent ethics committee or institutional review board at each participating center." @default.
• W4308399633 created "2022-11-11" @default.
• W4308399633 creator A5002903566 @default.
• W4308399633 creator A5007032179 @default.
• W4308399633 creator A5012674451 @default.
• W4308399633 creator A5027371764 @default.
• W4308399633 creator A5030323121 @default.
• W4308399633 creator A5030471739 @default.
• W4308399633 creator A5031420337 @default.
• W4308399633 creator A5036490187 @default.
• W4308399633 creator A5036875036 @default.
• W4308399633 creator A5042370614 @default.
• W4308399633 creator A5050155318 @default.
• W4308399633 creator A5053494596 @default.
• W4308399633 creator A5059797294 @default.
• W4308399633 creator A5069381611 @default.
• W4308399633 creator A5074746574 @default.
• W4308399633 creator A5089962252 @default.
• W4308399633 creator A5091142684 @default.
• W4308399633 date "2022-11-01" @default.
• W4308399633 modified "2023-10-16" @default.
• W4308399633 title "589 Xevinapant plus nivolumab in patients with advanced solid tumors who progressed on prior anti–PD-1/PD-L1 treatment: results of a dose-optimization, exploratory phase 1b/2 trial" @default.
• W4308399633 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0589" @default.
• W4308399633 hasPublicationYear "2022" @default.
• W4308399633 type Work @default.
• W4308399633 citedByCount "0" @default.
• W4308399633 crossrefType "proceedings-article" @default.
• W4308399633 hasAuthorship W4308399633A5002903566 @default.
• W4308399633 hasAuthorship W4308399633A5007032179 @default.
• W4308399633 hasAuthorship W4308399633A5012674451 @default.
• W4308399633 hasAuthorship W4308399633A5027371764 @default.
• W4308399633 hasAuthorship W4308399633A5030323121 @default.
• W4308399633 hasAuthorship W4308399633A5030471739 @default.
• W4308399633 hasAuthorship W4308399633A5031420337 @default.
• W4308399633 hasAuthorship W4308399633A5036490187 @default.
• W4308399633 hasAuthorship W4308399633A5036875036 @default.
• W4308399633 hasAuthorship W4308399633A5042370614 @default.
• W4308399633 hasAuthorship W4308399633A5050155318 @default.
• W4308399633 hasAuthorship W4308399633A5053494596 @default.
• W4308399633 hasAuthorship W4308399633A5059797294 @default.
• W4308399633 hasAuthorship W4308399633A5069381611 @default.
• W4308399633 hasAuthorship W4308399633A5074746574 @default.
• W4308399633 hasAuthorship W4308399633A5089962252 @default.
• W4308399633 hasAuthorship W4308399633A5091142684 @default.
• W4308399633 hasBestOaLocation W43083996331 @default.
• W4308399633 hasConcept C121608353 @default.
• W4308399633 hasConcept C126322002 @default.
• W4308399633 hasConcept C143998085 @default.
• W4308399633 hasConcept C203092338 @default.
• W4308399633 hasConcept C2777701055 @default.
• W4308399633 hasConcept C2779984678 @default.
• W4308399633 hasConcept C2780030458 @default.
• W4308399633 hasConcept C2780057760 @default.
• W4308399633 hasConcept C31760486 @default.
• W4308399633 hasConcept C535046627 @default.
• W4308399633 hasConcept C71924100 @default.
• W4308399633 hasConcept C72563966 @default.
• W4308399633 hasConcept C90924648 @default.
• W4308399633 hasConceptScore W4308399633C121608353 @default.
• W4308399633 hasConceptScore W4308399633C126322002 @default.
• W4308399633 hasConceptScore W4308399633C143998085 @default.
• W4308399633 hasConceptScore W4308399633C203092338 @default.
• W4308399633 hasConceptScore W4308399633C2777701055 @default.
• W4308399633 hasConceptScore W4308399633C2779984678 @default.
• W4308399633 hasConceptScore W4308399633C2780030458 @default.
• W4308399633 hasConceptScore W4308399633C2780057760 @default.
• W4308399633 hasConceptScore W4308399633C31760486 @default.
• W4308399633 hasConceptScore W4308399633C535046627 @default.
• W4308399633 hasConceptScore W4308399633C71924100 @default.
• W4308399633 hasConceptScore W4308399633C72563966 @default.
• W4308399633 hasConceptScore W4308399633C90924648 @default.
• W4308399633 hasLocation W43083996331 @default.
• W4308399633 hasOpenAccess W4308399633 @default.
• W4308399633 hasPrimaryLocation W43083996331 @default.
• W4308399633 hasRelatedWork W2581294190 @default.
• W4308399633 hasRelatedWork W2799275431 @default.
• W4308399633 hasRelatedWork W2890041342 @default.
• W4308399633 hasRelatedWork W2936810997 @default.
• W4308399633 hasRelatedWork W2978259179 @default.
• W4308399633 hasRelatedWork W3010513424 @default.
• W4308399633 hasRelatedWork W3120622126 @default.
• W4308399633 hasRelatedWork W3177224496 @default.
• W4308399633 hasRelatedWork W4304690509 @default.
• W4308399633 hasRelatedWork W4379282661 @default.
• W4308399633 isParatext "false" @default.
• W4308399633 isRetracted "false" @default.
• W4308399633 workType "article" @default.